Skip to content
Menu

Head-to-head comparison

Oak vs Vaylen

Two GLP-1 providers, one scorecard. Both are graded on the same six Desk Score dimensions — here is how they stack up, and which one fits you.

Ranked #136
Oak

A wide menu — compounded, oral or brand-name — at $200/mo for compounded semaglutide and $250 for tirzepatide, from a seller that names its pharmacy and never auto-renews. The catch is that Oak's own FAQ says each dose step adds about $50 to $75, on the same page whose banner promises one price at every dosage.

$200/mo (see conditions) sema · $250/mo (billed every 4 weeks) tirz · Verified August 2026

Marked down on: The banner on Oak's own order form says "One price · All dosages" while the FAQ at the bottom of that same page says every dose step is "approximately $50 - $75 more" and that you agree in advance to pay whatever the doctor prescribes

vs
Ranked #8Desk pick
Vaylen

The strongest all-rounder among the newer entrants — low pricing, brand access, oral routes, and all 50 states on one account.

$179/mo sema · $239/mo tirz

Marked down on: Newer operator with a shorter track record

Vaylen takes this head-to-head with the higher Desk Score, 90/100 (A−) against 71/100 (C) for Oak. Oak still holds its ground where its strengths line up with yours.

Desk Score, dimension by dimension

Same six measured dimensions for both. The red flag marks the stronger side. See the methodology.

Oak

71/100

C

Overall

Vaylen

90/100

A−

Price transparency

45
88

State access

95
96

Molecule range

62
96

Onboarding speed

92
86

Support responsiveness

72
84

Licensing & trust

70
90

The spec sheet

FieldOakVaylen
Semaglutide$200/mosee conditions$200/mo (compounded, list $250) on its own order form; Oak's FAQ says each dose step adds about $50 to $75, so this is a starting figure rather than a flat rate · oral semaglutide $245/mo · brand Ozempic $1,150/mo$179/mo$179/mo
Tirzepatide$250/mobilled every 4 weeks$250/mo (compounded, list $300) on its own order form; Oak's FAQ says each dose step adds about $50 to $75, so this is a starting figure rather than a flat rate · brand Zepbound $1,250/mo, brand Mounjaro $1,100 per 4 weeks$239/mo$239/mo
Coverage48 states (not West Virginia or Mississippi)All 50 states
Brand-nameYesYes
Oral optionYesYes
Best forPeople who want compounded, oral or genuine brand-name access from one order form, will read that form rather than the advertising, and have budgeted for a bill that rises as the dose does.People who want maximum optionality — brand or compounded, oral or injectable — without giving up nationwide reach.
Desk Score71/100C90/100A−

The verdict

Desk pick — Vaylen

Vaylen takes this head-to-head with the higher Desk Score, 90/100 (A−) against 71/100 (C) for Oak. Oak still holds its ground where its strengths line up with yours.

Choose Oak if…

People who want compounded, oral or genuine brand-name access from one order form, will read that form rather than the advertising, and have budgeted for a bill that rises as the dose does.

$200/mo (see conditions) sema · $250/mo (billed every 4 weeks) tirz · 48 states (not West Virginia or Mississippi)

Choose Vaylen if…

People who want maximum optionality — brand or compounded, oral or injectable — without giving up nationwide reach.

$179/mo sema · $239/mo tirz · All 50 states

Assume any provider we list may compensate us — we may earn a referral commission at no extra cost to you, and what we write about a provider reads the same either way. Read full breakdowns: Oak · Vaylen.

Also here

CoreAge Rx leads the whole ranking at 94/100

Whichever of these two you lean toward, our #1-rated provider outscores them both. One price at every dose, both molecules, all 50 states. The $99 and $149 figures are 12-month plans paid up front, not a monthly bill.

More head-to-heads

Or see the full comparison hub and the complete ranking.

Pricing and verification reflect each provider's public disclosures at last scoring; the Desk Score is our editorial judgment per the methodology. Prices change — confirm on each provider's own site. Not medical advice; see our disclosure.